Ferroptosis in Human Diseases: Fundamental Roles and Emerging Therapeutic Perspectives
Antioxidants · 26.11.2025 · 14 (12) · 1411
DOI: 10.3390/antiox14121411 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 26.11.2025. Verfasst von Ilaria Artusi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine (DMM), University of Padua, Via Ugo Bassi 58/B, 35131 Padua, Italy. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 231 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union.
Abstract (Originalsprache)
Ferroptosis is a novel iron-sensitive subtype of regulated cell death (RCD), persisting under extreme lipid peroxidation and iron/redox imbalances. Unlike apoptosis, necroptosis, and pyroptosis, ferroptosis is a signaling-driven process mediated through iron metabolism imbalance, polyunsaturated fatty acid (PUFA) exceeding oxidation, and defects in its protective systems like Xc-/GSH/GPx4. Specifically, this review establishes that iron-driven ferroptosis is a central underlying pathomechanistic factor in a broad range of human diseases. Significantly, whether its modulation is therapeutic, it is entirely conditional on the specific disease context. Thus, its induction can provide a promising antidote for destructive cancer cells when conjoined with immuno-therapies to boost anticancer immunity. Conversely, iron-mediated ferroptosis suppression is a key factor in countering destructive changes in a whole range of degenerative and acute injuries. Current therapeutic approaches include iron chelators, lipid oxidation inhibitors, GPx4 activators, natural and active compounds, and novel drug delivery systems. However, against all odds and despite its intense therapeutic promise, its translation into a practical medicinal strategy faces many difficulties. Thus, a therapeutic agent specifically focused on its modulation is still lacking. The availability of selective biologic markers is a concern. The challenges in the direct pathologic identification of ferroptosis in a complex in vivo systemic scenario remain. Current avenues for its future development are pathogen infections, the discovery of novel regulating factors, and novel approaches to personalized medicine centered on its organ-level in vivo signatures.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Medicine (DMM), University of Padua, Via Ugo Bassi 58/B, 35131 Padua, Italy.
- Department of Pharmaceuticals and Pharmacological Sciences (DSF), University of Padua, Via Marzolo 5, 35131 Padua, Italy.
- Biostructures and Biosystems National Institute (INBB), Via dei Carpegna 19, 00165 Rome, Italy.
ORCID-Profile: Ilaria Artusi, Michela Rubin, Giovanni Cravin, Giorgio Cozza
Förderung
- European Union
Zitieren
APA
Artusi, I., Rubin, M., Cravin, G., & Cozza, G. (2025). Ferroptosis in Human Diseases: Fundamental Roles and Emerging Therapeutic Perspectives. Antioxidants, 14(12), 1411. https://doi.org/10.3390/antiox14121411
Vancouver
Artusi I, Rubin M, Cravin G, Cozza G. Ferroptosis in Human Diseases: Fundamental Roles and Emerging Therapeutic Perspectives. Antioxidants. 2025;14(12):1411. doi:10.3390/antiox14121411
BibTeX
@article{Artusi2025,
author = {Artusi, Ilaria and Rubin, Michela and Cravin, Giovanni and Cozza, Giorgio},
title = {Ferroptosis in Human Diseases: Fundamental Roles and Emerging Therapeutic Perspectives},
journal = {Antioxidants},
year = {2025},
volume = {14},
number = {12},
pages = {1411},
doi = {10.3390/antiox14121411}
}
EUVIMED